eligibility_summary
Inclusion: 18–75, ECOG ≤1, MSS/pMMR colorectal adenocarcinoma with ≥1 evaluable metastasis, first-line–naive or post 1st-line failure/toxicity, prior RT ≥4 wks, adequate marrow/liver/renal labs, consent. Exclusion: abnormal counts/coagulation/proteinuria, uncontrolled HTN, active GI ulcer/bleeding/perforation/fistula, recent thrombosis/bleed/major heart disease, uncontrolled effusions, prior PD-1/PD-L1/CTLA-4, other recent cancers, HBV/HCV/cirrhosis, pregnancy, brain mets >3 cm or cord risk, poor compliance/psychiatric.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II, single-arm trial in MSS metastatic colorectal cancer testing: 1) Toripalimab (anti–PD-1 IgG4 monoclonal antibody) to block PD-1/PD-L1 and reinvigorate cytotoxic T cells, 2) Standard chemotherapies: 5-FU/capecitabine (antimetabolites, thymidylate synthase inhibition), oxaliplatin (platinum DNA crosslinker), irinotecan (topoisomerase I inhibitor), raltitrexed (TS inhibitor), 3) Targeted biologics: bevacizumab (anti–VEGF-A mAb, anti-angiogenesis) and cetuximab (anti-EGFR mAb, inhibits EGFR→MAPK/PI3K in RAS/RAF WT tumors), 4) Radiotherapy (SABR/HFRT high-dose, LDRT) to induce DNA damage, immunogenic cell death, antigen release, and TME modulation. Targets/pathways: PD-1 on T cells, EGFR pathway in RAS/RAF WT tumor cells, VEGF-driven endothelial angiogenesis, DNA replication/repair (TS, topo I), tumor microvasculature and immune infiltration via RT.